Characterizing Expected Benefits of Biomarkers in Treatment Selection by Huang, Ying et al.
UW Biostatistics Working Paper Series
11-15-2013
Characterizing Expected Benefits of Biomarkers in
Treatment Selection
Ying Huang
Fred Hutchinson Cancer Center, yhuang@fhcrc.org
Eric Laber
North Carolina State University, eblaber@ncsu.edu
Holly Janes
Fred Hutchinson Cancer Research Center, hjanes@fhcrc.org
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors
Suggested Citation
Huang, Ying; Laber, Eric; and Janes, Holly, "Characterizing Expected Benefits of Biomarkers in Treatment Selection" (November
2013). UW Biostatistics Working Paper Series. Working Paper 396.
http://biostats.bepress.com/uwbiostat/paper396
1 Introduction
In many clinical settings for disease prevention and control, there is significant heterogeneity
in patient response to an intervention. Biomarkers associated with this heterogeneity, such
as demographic or genetic characteristics, can be used to help patients and clinicians select
interventions such that a therapy is only delivered to a patient who is likely to benefit from
it. Examples of such treatment selection markers include: the K-RAS gene mutations for
selecting antiepidermal growth factor receptor therapy for colorectal cancer (Karapetis and
others, 2008; Allegra and others, 2009); the FGFR2 and MRP30 genes for selecting hormone
therapy in breast cancer prevention of postmenopausal women (Prentice and others, 2009;
Huang and others, 2011); and the Oncotype-Dx, a 21-gene score for selecting adjuvant
chemotherapy for the treatment of estrogen-receptor positive breast cancer (Paik and others,
2006; Harris and others, 2007; Albain and others, 2010).
Statistical measures of the value of a marker-based treatment selection rule are essential
in the development of treatment selection markers. The test of a marker by treatment inter-
action is a common strategy for identifying treatment selection markers, however, recently
there has been a growing emphasis on developing measures of treatment selection ability
which are directly linked to clinical outcomes (Janes and others, 2011). Much of this work
focuses on the effect of treatment on the targeted disease outcome of interest. For example,
the population benefit of using a marker-based treatment-selection strategy, defined as the re-
duction in population disease rate through treatment-selection (Song and Pepe, 2004; Zhang
and others, 2012ab, 2013; Zhao and others, 2012); the accuracy for classifying a subject
into treatment-effective or ineffective categories based on a potential outcomes framework
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(Huang and others, 2012); the difference in average treatment effect between marker-positive
group and the overall population (Foster and others, 2011); the distribution of the disease
risk difference conditional on a marker or marker model between comparative interventions
(Cai and others, 2011; Huang and others, 2012; Janes and others, 2013); and the average
treatment difference in a subgroup of subjects whose estimated treatment difference were
greater than some threshold (Zhao and others, 2013) all quantify, in some fashion, the im-
pact of the marker on the rate of disease. In addition to its effect on the targeted disease of
interest, an intervention may impact the population through other costs such as side effect
burden or monetary cost. Thus, another important consideration in assessing a treatment
selection rule is the proportion of subjects selected for treatment (Janes and others, 2013).
If two treatment selection strategies are equally effective in controlling population disease
rate, then the strategy that recommends fewer people for treatment is more appealing due
to less treatment cost. One approach to incorporate both the effect on targeted disease and
other treatment effects in the assessment of treatment selection markers, is to use a decision-
theoretic framework which puts the treatment effect on disease and additional treatment
effects on the same scale by means of a treatment/disease cost ratio. For example, one can
define a net benefit measure as the reduction in overall disease and treatment cost comparing
a marker-based treatment strategy with a default strategy of treating no one (Vickers and
others, 2007; Rapsomaniki and others, 2012; Janes and others, 2013).
While useful for comparing treatment selection strategies, the net benefit of a particular
marker-based strategy does not provide a direct quantification of the benefit gained by the
marker when treatment/disease cost ratio varies, since the default strategy of no treatment
may or may not be the optimal strategy absent the marker information. In this paper,
we develop the expected benefit, a new measure built upon the net benefit, to quantify the
benefit in treatment selection gained by adopting a marker-based rule. This measure quan-
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tifies the reduction in overall population cost due to both disease and treatment comparing
a marker-based treatment selection rule with the optimal treatment strategy absent the
marker information. The proposed method is built upon an earlier decision-theoretic frame-
work (Vickers and others, 2007; Rapsomaniki and others, 2012; Janes and others, 2013), but
further accommodates the fact that optimal treatment in the absence of marker information
varies with the cost of treatment. In addition, we propose a novel method to standardize
the expected benefit of a treatment selection strategy relative to the benefit that can po-
tentially be achieved via a perfect treatment selection rule. While the latter is in general
not identifiable, we show that upper and lower bounds instead can be established based on
a potential outcomes framework. Using a generalized linear model of disease risk as a func-
tion of marker and treatment, we consider the problem of maximizing the expected benefit
as a function of treatment/disease cost ratio. We develop model-based estimators for the
corresponding expected benefit and its standardized value in a randomized trial setting and
develop asymptotic theory for the estimators. The expected benefit is not a smooth function
of the generative model causing the standard bootstrap to fail; we develop a novel adaptive
bootstrap confidence interval that provides consistent inference. We also investigate alterna-
tive estimators of the optimal expected benefit based on a working model, which are robust
to model misspecification.
In Section 2, we introduce the concept of expected benefit, derive bounds on the expected
benefit of a perfect selection rule, and define the standardized expected benefit. We develop
estimation methods and theoretical results in Section 3. Simulation studies are presented in
Section 4 where we investigate finite sample performance of the estimators. Application of the
methodology to an example in the Diabetes Control and Complications Trial is presented
in Section 5 where we evaluate the expected benefit of the baseline hemoglobin A1C for
selecting diabetes treatment. We then summarize the paper and make concluding remarks.
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2 Methods
We consider the setting of a randomized trial with two arms, T = 0, 1 indicating the placebo
and treatment arms respectively. Let D be a binary outcome that the treatment targets,
which we call ‘disease,’ with D = 0, 1 indicating control and case status respectively. For
example, in a disease prevention setting, D may indicate disease status; whereas in the
setting of treating patients with an existing disease, D may indicate disease recurrence or
disease-related death. Let ρ0 = P (D = 1|T = 0) and ρ1 = P (D = 1|T = 1) indicate
disease prevalence in placebo and treatment arms. Let Y denote the, possibly multivariate,
biomarker of interest. Let A(Y ) be a treatment-selection rule based on the marker, which
takes value 1,0 corresponding to the recommendation for or against the treatment. Let i be
subject indicator. With a randomized trial with N participants, the data we observe are
i.i.d (Yi, Ti, Di), i = 1, . . . , N .
As in Vickers and others (2007), we assume the cost of the treatment either due to side
effects or due to monetary cost can be quantified as c times the cost per disease outcome,
where c is a non-negative utility parameter indicating the ratio of treatment cost relative
to disease cost. For example, in Vickers and others (2007) c was chosen to be 5% for
treating breast cancer with adjuvant therapy according to a patient survey; in Rapsomaniki
and others (2012), c was chosen to be 20% for preventing the emergence of cardiovascular
disease within 10 years using statin.
Without loss of generality, let the cost of per disease outcome be 1, then the total cost
due to disease and treatment averaged across a population for a strategy A(Y ) and for the
optimal treatment strategy absent the marker information can be computed respectively as
follows in units of disease cost.
For cost ratio c, the population-averaged total cost due to disease and treatment by
applying a treatment selection rule A(Y ) is EA(D)+P{A(Y ) = 1}×c, where the expectation
4
http://biostats.bepress.com/uwbiostat/paper396
EA(D) is taken with respect to the rule A(Y ). Based on a randomized trial where T is
randomized to subjects, the cost can be expressed as
P{D = 1, A(Y ) = 0|T = 0} + P{D = 1, A(Y ) = 1|T = 1}+ P{A(Y ) = 1} × c
= P (D = 1|T = 0)− [E{DA(Y )|T = 0}+ E{DA(Y )|T = 1}] + E{A(Y )} × c
= ρ0 − E [A(Y ) {∆(Y )− c}] , (1)
where ∆(Y ) = P (D = 1|T = 0, Y ) − P (D = 1|T = 1, Y ) is the risk difference conditional
on Y between placebo and treatment arms.
Without any biomarker information, the optimal treatment selection rule that minimizes
the total disease plus treatment cost is to treat everyone if ρ0 − ρ1 > c and treating no one
otherwise. Thus, the total cost based on this treatment selection rule is
ρ0 − [ρ0 − ρ1 − c]+ , (2)
where [u]+ = max(0, u) is the positive-part function.
We define the expected benefit EBA(c) for a treatment-strategy A(Y ) and cost ratio c
as the difference between (2) and (1), i.e., the reduction in the total cost using A(Y ) relative
to the optimal rule in the absence of biomarkers:
EBA(c) = E [A(Y ) {∆(Y )− c}]− [ρ0 − ρ1 − c]+ . (3)
Note that the first component of (3) is exactly the net benefit measure considered by Vickers
and others (2007), Rapsomaniki and others (2012), and Janes and others (2013). That is, the
expected benefit equals the net benefit when the optimal strategy absent marker information
is to treat no one. The second component of (3) can be viewed as the net benefit of an
optimal treatment selection rule absent any marker information. Thus, the expected benefit
of a marker-based treatment selection rule can be interpreted as the incremental value in
net benefit compared to the optimal treatment strategy without the biomarker. In other
5
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words, if one computes the improvements in the net benefit for the marker guided treatment
selection strategy versus two potential strategies: treating everyone and treating no one,
then the minimum of the two incremental values corresponds to the expected benefit of the
marker-based strategy.
In practice, it is difficult to agree upon one single utility parameter c. Rather an expected
benefit curve of EBA(c) versus c can be used. Examples of expected benefit curves are shown
in Figures 1 (a)(b), which we describe in more detail in next section. Hereafter, to simplify
notation we write EB(c) with the understanding that a underlying strategy A(Y ) is implicitly
involved.
2.1 Perfect Treatment Selection and Standardized Expected Ben-
efit
In this section, we define the expected benefit for a perfect treatment selection rule which
can be used to standardize the expected benefit of a marker-based rule. This type of stan-
dardization makes the measure of benefit invariant to the choice of disease cost. Thus, it
puts the measure on a relative scale between 0 and 1 which is common across different set-
tings where marker, treatment, disease, and study populations may differ. Standardization
has been commonly performed with measures of a biomarker’s capacity for risk prediction,
(e.g., the standardized total gain (Bura and Gastwirth, 2001; Huang and Pepe, 2009; Gu
and Pepe, 2009) and the relative utility curve (Baker and others, 2009)), but not yet for
treatment selection.
We define the new concept of a perfect treatment selection rule using a potential out-
comes framework. Let D(0), D(1) denote the pair of potential outcomes if a subject receives
placebo or treatment respectively. The four possible values of D(0), D(1) are shown below
with q1, . . . , q4 denoting the unobserved population proportion of subjects falling into each
category. Subjects with D(0) = 1, D(1) = 0 can be described as treatment-benefitted, sub-
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jects with D(0) = D(1) = 1 or D(0) = D(1) = 0 are treatment-unaffected, and subjects
with D(0) = 0, D(1) = 1 are treatment-harmed, where benefits and harms are with respect
to the targeted disease of interest.
D(0) D(1) proportion
1 0 benefitted q1
1 1 unaffected q2
0 0 unaffected q3
0 1 harmed q4
For a particular cost ratio c ≥ 0, a perfect treatment selection rule will identify all treatment-
benefitted subjects for treatment and recommend against treatment for others. This will lead
to a population-averaged total disease and treatment cost of q2 + q1c = ρ0 − q1+ q1c, which
corresponds to expected benefit PEB(c) = q1(1− c)− [ρ0 − ρ1 − c]+.
While in general q1 is not identifiable in the observed data, upper and lower bounds can
be identified using a disease risk model. Let qk(Y ), k = 1, 2, 3, 4 indicate the probability
that a subject with marker Y falls into the ith potential outcome category, and let ρ0(Y ) =
P (D = 1|Y, T = 0), ρ1(Y ) = P (D = 1|Y, T = 1). We have
q1(Y ) + q2(Y ) = ρ0(Y )⇒ q1(Y ) ≤ ρ0(Y ),
q1(Y ) + q3(Y ) = 1− ρ1 ⇒ q1(Y ) ≤ 1− ρ1(Y ),
q1(Y )− q4(Y ) = ρ0(Y )− ρ1(Y )⇒ q1(Y ) ≥ ρ0(Y )− ρ1(Y ),
which impliesmax{0, ρ0(Y )−ρ1(Y )} ≤ q1(Y ) ≤ min{ρ0(Y ), 1− ρ1(Y )}. Taking an expecta-
tion over Y , we haveE
[{∆(Y )}+] ≤ q1 ≤ ρ0−E [{ρ0(Y ) + ρ1(Y )− 1}+] . Note that alterna-
tive nonparametric bounds for q1 can be derived without relying on any biomarker or model
information: max(0, ρ0−ρ1) = [E{∆(Y )}]+ ≤ q1 ≤ min(ρ0, 1−ρ1) = ρ0−[E{ρ0(Y )+ρ1(Y )−
1}]+. Incorporating risk model information nevertheless leads to narrower bounds of q1 since
[E{∆(Y )}]+ ≤ E [{∆(Y )}+] and [E{ρ0(Y )+ρ1(Y )−1}]+ ≤ E
[{ρ0(Y ) + ρ1(Y )− 1}+], and
will be the focus of this paper. These types of restrictions on the probability of potential
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outcome category have also been recognized by others, e.g., Gadbury and others (2004);
Huang and others (2012); Zhang and others (2013).
Based on the model of the risk of D conditional on Y and T , we can construct a lower
bound for the expected benefit of a perfect treatment selection rule as
PEBl(c) = E [{∆(Y )}+]× (1− c)− [ρ0 − ρ1 − c]+ , (4)
and an upper bound
PEBu(c) = (ρ0 − E [{ρ0(Y ) + ρ1(Y )− 1}+])× (1− c)− [ρ0 − ρ1 − c]+ . (5)
In summary, the uncertainty in identifying the expected benefit of a perfect treatment selec-
tion marker is caused by the non-identifiability of the percent of “benefitted” individuals, in
other words, the inability to separate “benefitted” individuals from “unaffected” individuals
among diseased subjects in the placebo arm. In the special case where the treatment has a
monotone effect on the targeted disease and will not cause any harm (so q4 = 0), we have
q1 = ρ0−ρ1. Thus, under monotonicity the expected benefit of a perfect treatment selection
rule can be uniquely identified as (ρ0 − ρ1) × (1− c) − [ρ0 − ρ1 − c]+, which is equal to its
lower bound in (4) since E [{∆(Y )}+] = E{∆(Y )} = ρ0 − ρ1 under monotonicity.
Finally, dividing the expected benefit of a marker-based treatment strategy by the bounds
of expected benefit from perfect treatment selection, we obtain bounds for the standardized
expected benefit: SEBl(c) = EB(c)/PEBu(c) and SEBu(c) = EB(c)/PEBl(c).
Expected benefit from a perfect treatment selection sets a reference for gauging the benefit
of a particular treatment selection rule or the difference in benefit between treatment selection
rules. In Figures 1(a)(b), we show the expected benefit of two treatment selection markers
and lower and upper bounds for perfect treatment selection derived from corresponding
marker-based risk model. Marker 1 (Figure 1(a)) has small expected benefit with a large
potential for improvement. For example, at a cost ratio 0.05, its expected benefit of 0.005
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is far from the perfect selection rule: a perfect selection rule can have an expected benefit
8.8-26.9 times that of Marker 1; corresponding standardized expected benefit for Marker 1
at cost ratio 0.05 ranges between 3.7% and 11.4% (Figure 1(c)). In contrast, there is less
potential to improve over a better marker (Marker 2) (Figure 1(b)). At a cost ratio 0.05, a
perfect selection rule can have expected benefit 1.7-2.8 times that of Marker 2, which has
expected benefit 0.05 and standardized value ranging from 35.7% to 58.0% (Figure 1(d)).
3 Derivation of Treatment Selection Rules for Opti-
mizing Expected Benefit
In this section, we consider methods for maximizing the expected benefit of a marker-based
treatment selection rule and for estimating the benefit and its standardized value for varying
c. We first need to construct a treatment selection rule A(Y ). In this paper we consider the
class of selection rules A(Y ) which compare h(Y ), a function of Y with a threshold value δ
to be determined, where h(Y ) is constructed by fitting a generalized linear model (GLM) of
D on Y and T . Next we propose two strategies for optimizing the selection rule A(Y ) and
calculating (standardized) expected benefit. Both methods use the same strategy to find
h(Y ), but differ in the determination of δ. The first relies on a well-calibrated model for
risk difference ∆(Y ), the second does not and is thus more robust to model-misspecification.
The first strategy however is more efficient under a correctly specified model.
3.1 Model-Based Approach
Based on equation (1), it can be seen that a marker-based rule A(Y ) that optimizes expected
benefit at cost ratio c is equal to 1 whenever ∆(Y ) > c and 0 otherwise. For details see, for
example, Vickers and others (2007) and Janes and others (2013).
We consider modeling the risk of D conditional on Y and T with g{P (D = 1|Y, T )} =
β0+ β1T + β
T
2 Y + β
T
3 Y T, where g is a known link function, for example, the logit or inverse
9
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normal CDF. Let βˆ denote the maximum likelihood estimator (MLE) of β, and let ∆ˆ(Y )
denote the corresponding estimator of ∆(Y ). When the model for risk difference is well-
calibrated, i.e., when ∆ˆ(Y ) is a good estimator of ∆(Y ), a model based estimator of expected
benefit can be constructed based on (1): ÊB(c) =
∑N
i=1
(
∆ˆi − c
)
+
/N−
(∑N
i=1 ∆̂i/N − c
)
+
,
where ∆ˆi = ∆ˆ(Yi) is the estimate of ∆ for subject i. Note that a good calibration of the risk
model itself is sufficient for the risk difference ∆ to be well-calibrated, but not necessary.
Hosmer-Lemeshow type techniques can be used for evaluating both types of calibrations
(Hosmer and Lemesbow, 1980; Huang and Pepe, 2010; Janes and others, 2013).
We estimate the lower bound on the expected benefit of a perfect treatment selection
rule as P̂EB
l
(c) =
∑N
i=1
(
∆ˆi
)
+
× (1 − c)/N −
(∑N
i=1 ∆ˆi/N − c
)
+
and the upper bound
as P̂EB
u
(c) =
∑N
i=1
{
R̂isk0i −
(
R̂isk0i + R̂isk1i − 1
)
+
}
× (1− c)/N−
(∑N
i=1 ∆ˆi/N − c
)
+
,
where R̂isk0 and R̂isk1 are model-based estimates of P (D = 1|Y, T = 0) and P (D = 1|Y, T =
1) respectively. Corresponding lower and upper bounds on SEB(c) can be estimated as
ÊB(c)/P̂EB
u
(c) and ÊB(c)/P̂EB
l
(c). Next we present asymptotic theory for the model-
based estimators.
3.2 Asymptotic Theory for the Model-Based Estimator
Under standard regularity conditions listed in Supplementary Appendix, when ρ0 − ρ1 6= c,
ÊB(c), P̂EB
l
(c), and P̂EB
u
(c) are asymptotically normal as stated in Theorems 1 and 2.
Theorem 1 Under the specified regularity conditions, ÊB(c) is asymptotically normally
distributed as N →∞ for c 6= ρ0 − ρ1. In particular, we have
√
N
{
ÊB(c)− EB(c)
}
=
1√
N
N∑
i=1
{Ψ1i +Ψ2i − I(ρ0 − ρ1 > c) (Ψ3i +Ψ4i)}+ op(1),
where
Ψ1i =
∂EB(c)
∂β
I−1(β)l(β)i, Ψ2i = (∆i − c)+ − E {(∆− c)+} ,
Ψ3i =
∂E{∆(β)}
∂β
I−1(β)l(β)i, Ψ4i = ∆i − (ρ0 − ρ1),
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with I(β) and l(β) the information matrix and efficient influence function for P (D|Y, T ).
Theorem 2 Under the specified regularity conditions, P̂EB
l
(c) and P̂EB
u
(c) are asymp-
totically normally distributed as N →∞ for c 6= ρ0 − ρ1. In particular:
(i)
√
N
{
P̂EB
l
(c)− PEBl(c)
}
=
1√
N
N∑
i=1
{(1− c) (Ψ5i +Ψ6i)− I(ρ0 − ρ1 > c) (Ψ3i +Ψ4i)}+op(1),
(ii)
√
N
{
P̂EB
u
(c)− PEBu(c)
}
=
1√
N
N∑
i=1
{(1− c) (Ψ7i +Ψ8i)− I(ρ0 − ρ1 > c) (Ψ3i +Ψ4i)}+ op(1),
where
Ψ5i =
∂E(∆+)
∂β
I−1(β)l(β)i, Ψ6i = (∆i)+ − E(∆+),
Ψ7i =
∂ [E{Risk0(β)} − E{Risk0(β) +Risk1(β)− 1}+]
∂β
I−1(β)l(β)i,
Ψ8i = Risk0i(β)− {Risk0i(β) +Risk1i(β)− 1}+ − [ρ0 −E{Risk0(β) +Risk1(β)− 1}+] .
When c 6= ρ0 − ρ1, asymptotic normality of ŜEB(c)l and ŜEB(c)u then follows from Theo-
rems 1 and 2 and the Delta method.
When c = ρ0 − ρ1, it can be shown that
√
N
{(∑N
i=1 ∆ˆi/N − c
)
+
− (ρ0 − ρ1 − c)+
}
converges to a mixture of 0 and a truncated normal distribution. As a result, asymptotic
normality of ÊB(c), P̂EB(c), or ŜEB(c) does not hold. Even when asymptotic normality
of these estimators does hold, we recommend the bootstrap for constructing confidence
intervals since computation of the asymptotic variance of these estimators requires numerical
differentiation. In practice, standard bootstrap percentile CI can lead to undercoverage when
c ≈ ρ0−ρ1, we adopt an adaptive bootstrap confidence interval following the ideas of Berger
and Boos (1994), Laber and Murphy (2011), and Robins (2004). Specifically, the proposed
interval is equivalent to the standard bootstrap percentile CI when c is far from ρ0− ρ1 and
is equivalent to a projection interval otherwise, which is the union of bootstrap intervals as
11
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described below. Because the behavior of the confidence interval is automatically dictated
by the data, we term it ‘adaptive.’
Let b = 1, . . . , B index bootstrap samples drawn from the original data with replacement.
We add a superscript b, to indicate that a statistic has been computed using a bootstrap sam-
ple. We construct an adaptive projection confidence interval as follows. For any r ∈ R define
ÊB
b
r(c) =
∑N
i=1
(
∆ˆbi − c
)
+
/N−
(∑N
i=1 ∆̂
b
i/N − c
)
I(r > 0), P̂EB
lb
r (c) =
∑N
i=1
(
∆ˆbi
)
+
×(1−
c)−
(∑N
i=1 ∆ˆ
b
i/N − c
)
+
I(r > 0), and P̂EB
ub
r (c) =
∑N
i=1
{
R̂isk
b
0i −
(
R̂isk
b
0i + R̂isk
b
1i − 1
)
+
}
/N×
(1− c) −
(∑N
i=1 ∆ˆ
b
i/N − c
)
I(r > 0). Let ζEB(c),η(r), ζPEBl(c),η(r), and ζPEBu(c),η(r) denote
(1 − η) × 100% percentile bootstrap confidence intervals formed by taking empirical per-
centiles of ÊB
b
r(c), P̂EB
lb
r (c), and P̂EB
ub
r (c) over bootstrap samples respectively. Let Γα(c)
denote an asymptotically valid (1 − α) × 100% confidence interval for ρ0 − ρ1 − c. The
(1 − η − α) × 100% projection intervals for EB(c), PEBl(c) and PEBu(c) are given re-
spectively by
⋃
r∈Γα(c)
ζEB(c),η(r),
⋃
r∈Γα(c)
ζPEBl(c),η(r), and
⋃
r∈Γα(c)
ζPEBu(c),η(r). Let P
b
denote probability taken with respect to the bootstrap sampling algorithm, conditional on
the observed data. The following results (Theorem 3 and Corollary 1) are proved in the
Supplementary Appendix B.
Theorem 3 [Projection bootstrap intervals] Assume ∆(Y ) has a continuous and bounded
density function. Let α, η ∈ (0, 1), and let c be fixed. Then,
1. P b
(
EB(c) ∈ ⋃r∈Γα(c) ζEB(c),η(r)) ≥ 1− α − η + op(1);
2. P b
(
PEBl(c) ∈ ⋃r∈Γα(c) ζPEBl(c),η(r)) ≥ 1− α− η + op(1);
3. P b
(
PEBu(c) ∈ ⋃r∈Γα(c) ζPEBu(c),η(r)) ≥ 1− α− η + op(1).
If E∆(Y ) 6= c then the right hand side of the foregoing inequalities can be replaced with
equality to 1− η + oP (1).
12
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Corollary 1 Let τN be a sequence of positive random variables satisfying τN → 0 and
√
NτN → ∞ almost surely as N → ∞. Define A(c) = Γα(c) if |ρˆ0 − ρˆ1 − c| ≤ τN and
{∑Ni=1 ∆ˆi/N − c} otherwise. Assume the conditions of Theorem 3. Then,
1. P b
(
EB(c) ∈ ⋃r∈A(c) ζEB(c),η(r)) ≥ 1− α− η + op(1);
2. P b
(
PEBl(c) ∈ ⋃r∈A(c) ζPEBl(c),η(r)) ≥ 1− α− η + op(1);
3. P b
(
PEBu(c) ∈ ⋃r∈A(c) ζPEBu(c),η(r)) ≥ 1− α − η + op(1).
If E∆(Y ) 6= c then the right hand side of the foregoing inequalities can be replaced with
equalities. Note that for |ρˆ0 − ρˆ1 − c| > τN ,
⋃
r∈A(c) ζEB(c),η(r),
⋃
r∈A(c) ζPEBl(c),η(r), and⋃
r∈A(c) ζPEBu(c),η(r) in the corollary refer to standard (1 − η) × 100% bootstrap confidence
interval for EB(c), PEBl(c) and PEBu(c).
Remark 1. Berger and Boos (1994) recommend choosing α to quite small in which case
1 − η ≈ 1 − η − α. Consequently, the originally proposed projection confidence interval is
nearly exact in large samples provided E∆(Y ) 6= c, but potentially conservative otherwise.
However, Corollary 1 suggests a procedure which provides exact coverage when E∆(Y ) 6= c
and is thus both adaptive and less conservative than the projection interval. For these
reasons, it is recommended in practice.
Remark 2. The conditions of the preceding theorem can be relaxed at the expense of
a possibly more conservative confidence interval. In the Supplementary Appendix C we
provide a locally consistent projection confidence interval that does not require ∆(Y ) have
smooth bounded density. However, this interval requires taking a union over a larger set and
is thus potentially more conservative in some settings. We defer the detailed investigation
of this CI to future work.
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3.3 Robust Estimation Methods
The validity of the model-based approach for estimating the expected benefit of an optimal
treatment selection rule depends critically on model calibration. In practice, one may adopt
a working model ∆? based on a GLM and focus on constructing a decision rule A(Y ) =
I{∆?(Y ) ≥ δ} that has large benefit regardless of whether or not ∆? is well-calibrated.
Write the expected benefit based on ∆? and threshold δ asE{I(∆?(Y ) > δ) {∆(Y )− c}}−
[ρ0 − ρ1 − c]+ , which in a randomized trial can be represented as
{P (D = 1|∆?(Y ) > δ, T = 0)− P (D = 1|∆?(Y ) > δ, T = 1) − c}P (∆?(Y ) > δ)
− [ρ0 − ρ1 − c]+ , (6)
and estimated nonparametrically by
∑N
i=1Di
(
∆ˆ?i > δ
)
(1− Ti)∑N
i=1
(
∆ˆ?i > δ
)
(1− Ti)
−
∑N
i=1Di
(
∆ˆ?i > δ
)
Ti∑N
i=1
(
∆ˆ?i > δ
)
Ti
− c
 1N
N∑
i=1
(
∆ˆ?i > δ
)
−
[∑N
i=1 Yi(1− Ti)∑N
i=1(1− Ti)
−
∑N
i=1 Yi(Ti)∑N
i=1 Ti
− c
]
+
. (7)
A natural nonparametric analogue of the model-based estimator based on threshold value c
can be constructed by entering δ = c into (7). This estimator is unbiased for the expected
benefit of A(Y ) = ∆?(Y ) > c whether or not ∆? is well calibrated. However, when ∆? is not
well-calibrated, the rule based on comparing ∆? with c is not optimal among all rules of the
form ∆? > δ. An optimal δ among this class that maximizes (6) can instead be identified
by maximizing (7) over δ. Furthermore, following Zhang and others (2012), an augmented
version of (7) can be constructed as
(7) +
1
N
N∑
i=1
Ti
(
∆ˆ?i > δ
)
+ (1− Ti)
(
∆ˆ?i ≤ δ
)
− pi(Y, δ)
pi(Y, δ)
×{
R̂isk1 × I(∆ˆ?i > δ) + R̂isk0 × I(∆ˆ?i ≤ δ)
}
, (8)
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where pi(Y, δ) = P (T = 1)(∆ˆ? > δ) + P (T = 0)(∆ˆ? ≤ δ). The optimal δ can be constructed
as the maximizer of (8) for potential efficiency gain. These robust estimation methods are
aimed for scenarios where risk model is prone to misspecification. Since validity of the model-
based bounds in (4) and (5) for perfect selection benefit relies on well-calibrated risk model,
here we do not consider those bounds anymore.
Let δˆ be the estimate of δ through maximization of either (7) or (8), the corresponding
value of expected benefit in the training data tends to overestimate the true expected benefit
of the rule A(Y ) = ∆ˆ? > δˆ. In practice one can use cross-validation to correct for this bias,
as we demonstrate in our simulation studies.
4 Simulation Studies
In this section, we conduct simulation studies to investigate our estimators of (standardized)
expected benefit. We consider a two-arm 1:1 randomized trial with T = 0 and T = 1 indicat-
ing placebo and treatment arm respectively. Assume we have a biomarker Y which follows
standard normal distribution, we consider a linear logistic model for the risk of a binary dis-
ease D conditional on Y and T : logitP (D = 1|Y, T ) = β0+β1T+β2Y +β3Y T . The risk model
parameters are chosen such that disease prevalences are ρ0 = 0.25 and ρ1 = 0.125 in placebo
and treatment arm respectively. We consider cost ratios c = 0, 0.105, 0.125, 0.145, 0.175,
which correspond to expected benefit value of 0.043, 0.059, 0.063, 0.048, 0.029. The pairs
of lower and upper bounds for expected benefit from perfect treatment selection equal to
{0.043, 0.098}, {0.130, 0.180}, {0.147, 0.196}, {0.144, 0.191}, and {0.139, 0.184} respectively.
Sample sizes of 200, 500, and 2000 are used in the simulation studies.
Performance of the model-based estimators for EB(c), PEB(c) and SEB(c) are shown
in Tables 1 and 2. With a sample size of 200, model-based estimators have minimal bias
for each measure. Coverage of 95% percentile bootstrap CI is close to nominal level when
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c is away from ρ0 − ρ1, whereas an under-coverage is observed when c = ρ0 − ρ1, which is
not alleviated with the increase of sample size. The adaptive bootstrap CI fixes the under-
coverage problem where we use the projection interval (with α = 0.01) when estimated
ρ0 − ρ1 is close to c (defined as |ρˆ0 − ρˆ1 − c| ≤ SˆE (ρˆ0 − ρˆ1) × Φ−1(0.9) in the simulation
study).
If we use the same threshold c for risk difference but use a nonparametric method instead
for estimating EB(c), a decrease of efficiency is observed compared to the model-based esti-
mator (details omitted). In our simulation setting, variances of the model-based estimators
are around 40% ∼ 70% of the variances of the nonparametric estimators.
Based on the same logistic model fitting, we further consider finding δˆ by maximizing
the empirical estimate of EB(c) (7) and its augmented version (8). Table 3 presents perfor-
mance of the derived treatment decision rule using δˆ versus using δ = c in the population.
Estimating δ leads to a rule with smaller expected benefit with larger variability for small
sample size of 200, but has small impact on treatment selection performance when sample
size is as large as 2000. In general, using the augmented estimator for δ estimation leads
to small increase in treatment selection performance and decreased variability. Note that
under correct model specification, the estimated expected benefit based on robust methods
is expected to be suboptimal compared to the model-based estimator. It is when the model
is misspecified that the robust estimation methods may yield higher expected benefit.
In Supplementary Table 1, we present results for estimating expected benefit of treatment
selection rule ∆ˆ? > δˆ, using naive estimators based on the training data or alternative
estimators based on random cross-validation. For the latter, we randomly split the data
into 2/3 of training set and 1/3 of test set, fitting a logistic model to the training data
and compute δˆ, then compute the expected benefit based on the test data. An average of
expected benefit is computed over 500 splits. We see that expected benefit estimated from
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training data can have severe over-estimation even with a sample size as large as 2000, which
is corrected by cross-validation. Also presented in Supplementary Table 1 are naive and CV
estimates for expected benefits using the model-based rule. Here the over-fitting in naive
estimate is much less severe compared to nonparametric estimator and is minimal when
sample size goes above 500.
5 Data Example
In this section, we illustrate the estimation of expected benefit using an example from the
Diabetes Control and Complications Trial (DCCT) (Control and Group, 1993). DCCT was
a large-scale randomized controlled trial designed to compare intensive and conventional
diabetes therapy with respect to their effects on the development and progression of the
early vascular and neurologic complications of diabetes. Overall 1441 patients with insulin-
dependent diabetes mellitus were enrolled from 1983 to 1999, including 726 primary preven-
tion cohort patients who were free of any microvascular complications and 715 secondary
prevention cohort patients who had mild preexisting retinopathy or other complications.
Their appearances of progression of retinopathy and other complications assessed regularly
and the trial was terminated on 1999 with significant evidence of treatment efficacy resulting
in an average followup of 6.5 years.
One outcome of which the treatment in DCCT shows significant effect in reducing the
risk is micro-albuminuria, a sign of kidney damage, defined as albumin excretion rate greater
than 40mg/24hr. Our analysis here consists of 579 subjects in the secondary prevention co-
hort who did not have micro-albuminuria and neuropathy at baseline. We consider baseline
homoglobin A1C (HBA1C) as a biomarker for selecting treatment: a linear logistic regres-
sion model of micro-albuminuria developed during the study versus treatment and baseline
HBA1C and their interaction shows a significant interaction between treatment and HBA1C.
We estimate the expected benefit of HBA1C and its standard value. The curve of model-
17
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based estimator of EB(c) versus c is presented in Supplementary Figure 1(a). Also displayed
are estimated lower and upper bounds of expected benefit for perfect treatment selection.
Corresponding bounds for standardized expected benefit of HBA1C are displayed in Sup-
plementary Figure 1(b). For a series of chosen cost ratio, the model-based estimates and
their 95% CI are shown in Table 4. For example, at cost ratio c = 0, i.e., no cost of more
intensive diabetes therapy, HBA1C has a EB of 0.005 while the EB of a perfect treatment
selection rule can range from 0.005 to 0.206, such that standard EB of HBA1C is above
2.3%. For a bigger cost ratio such as c = 0.05, i.e., the cost of intensive therapy is 5% the
cost of micro-albuminuria, HB1AC has EB of 0.019, which explains 8% - 38.8% benefits of a
perfect treatment selection rule. Supplementary Table 2 presents cross-validated EB for the
model-based estimator and for the robust estimators where the selection threshold is non-
parametrically derived. In general we see reduction in EB resulted from CV. Optimization
of the threshold leads to slightly better CV estimate compared to model-based estimator.
6 Concluding Remarks
In this paper we developed an expected benefit measure for characterizing the capacity of
biomarkers in treatment selection. Built upon a decision-theoretic framework, this measure
integrates the benefit of a marker-based treatment selection rule on reducing population dis-
ease rate with the additional treatment cost through the specification of a treatment/disease
cost ratio. We also developed a new concept of a perfect treatment selection rule in the
sense that it correctly makes treatment recommendation for patients according to whether
or not they will benefit from the treatment. We developed bounds for expected benefit of
a perfect treatment selection rule based on the model of disease risk conditional on marker
and treatment. These bounds can be used to standardize the expected benefit of a treatment
selection rule, potentially facilitating comparison of markers across different study settings.
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The idea of generating bounds for treatment selection can be readily applied to other treat-
ment selection measures such as the population disease rate resulted from treatment selection
(Song and Pepe, 2004). An interesting fact about these model-based bounds is that their
width depends on how well the risk model used to construct the bounds can identify the
percent of “benefitted” in the population. A model that better predicts heterogeneity in
treatment responses in terms of larger variability in ∆ tends to move up the lower bound
for PEB through the increase of E{∆(Y )}+. In other words, tighter bounds reflect a better
knowledge in selecting treatment-benefitted subjects. In particular, in the scenario where
we compare two nested models, sharper bounds for perfect treatment selection can be esti-
mated from the more complicated model. In general when we have several risk models in a
population to assess expected benefit of perfect treatment selection. Tighter bounds can be
constructed using bounds derived from individual risk model. Specifically, at a given cost
ratio, the minimum benefit of perfect selection can be constructed as the maximum among
corresponding values in individual lower bounds, and the maximum benefit of perfect selec-
tion can be constructed as the minimum among corresponding values in individual upper
bounds.
We considered the problem of maximizing the expected benefit based on a GLM and
proposed two strategies. The model-based estimator was more efficient under well-calibrated
models whereas the nonparametric and augmented estimators were robust to misspecification
of working model and provided a way for sensitivity analysis. One advantage of using the
common GLM method for deriving the treatment selection rule is the computation simplicity
as the GLM model can be easily implemented with standard statistical software. We note
that there are alternative ways to construct the treatment selection rule A(Y ) in the field,
such as maximizing the measure of interest directly as adopted in Zhang and others (2012ab,
2013), and Zhao and others (2012); expected benefit of the treatment selection rule derived
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can be similarly estimated, through procedures such as cross-validation. To make inference
using the proposed model-based estimator, we proposed an adaptive bootstrap procedure
to handle the presence of non-regularity when cost ratio is close to the average treatment
effect. This idea of using data to adaptively construct bootstrap confidence interval has a
great potential to be used in other types of biomarker evaluation and comparison problems
where non-regularity can occur at some point in the parameter space.
In this paper, we consider cost ratio c to be a constant and a series of c can be chosen for
sensitivity analysis. In practice, the cost ratio might be a function of biomarker. For example,
the cost of mammography use for breast cancer prevention might depend on women’s age
(Gail, 2009). It is straightforward to extend the concept of expected benefit allowing c =
C(Y ) to be a function of biomarker value in scenarios where information is available for
modeling C(Y ) as proposed in Janes and others (2013).
Finally, while the concepts of perfect and/or standardized expected benefits are restricted
to binary disease outcomes, the concept of expect benefit itself and the methods developed
can be readily generalized to handle continuous outcomes.
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Table 2: Performance of the Model-Based Estimator for Bounds of PEB(c) and SEB(c).
Cost ratio c 0.000 0.105 0.125 0.145 0.175 0.000 0.105 0.125 0.145 0.175
PEBu(c) PEBl(c)
0.098 0.180 0.196 0.191 0.184 0.043 0.130 0.147 0.144 0.139
N Bias×1000
200 -0.10 -11.73 -20.31 -12.08 -4.93 2.02 -9.82 -18.45 -10.27 -3.18
500 -0.53 -5.53 -13.37 -6.04 -2.00 1.22 -3.97 -11.84 -4.55 -0.56
2000 -0.28 -0.98 -6.38 -1.02 -0.32 0.24 -0.51 -5.92 -0.57 0.11
SE ×√N
200 0.33 0.29 0.31 0.34 0.39 0.29 0.25 0.28 0.32 0.38
500 0.33 0.30 0.32 0.37 0.44 0.29 0.26 0.29 0.36 0.43
2000 0.34 0.32 0.32 0.43 0.45 0.29 0.28 0.30 0.42 0.45
Coverage of 95% percentile bootstrap CI
200 94.90 88.20 77.80 90.70 95.90 95.10 89.60 78.70 92.70 96.70
500 94.50 91.50 77.70 93.80 95.50 95.10 94.20 80.70 96.10 95.50
2000 94.50 95.80 80.10 96.50 95.00 94.50 96.40 82.20 96.70 95.20
Coverage of 95% adaptive bootstrap CI
200 94.90 94.28 91.08 93.98 95.84 95.14 95.04 91.22 94.90 96.62
500 94.52 95.02 91.44 94.72 95.50 95.08 96.26 92.02 96.36 95.62
2000 94.50 96.08 96.38 96.54 95.04 94.48 96.44 96.32 96.56 95.24
SEBl(c) SEBu(c)
0.436 0.327 0.323 0.253 0.156 1.000 0.452 0.429 0.336 0.207
N Bias×1000
200 9.12 -30.47 -58.66 -27.63 4.30 0.00 -42.79 -74.27 -39.34 -0.86
500 10.19 -10.73 -38.06 -12.60 3.42 0.00 -17.01 -47.53 -19.03 0.24
2000 2.66 -0.74 -19.51 -0.96 2.05 0.00 -2.30 -23.24 -2.43 1.36
SE ×
√
N
200 2.02 1.23 1.24 1.31 1.36 0.00 1.41 1.46 1.57 1.65
500 2.12 1.25 1.27 1.45 1.60 0.00 1.38 1.44 1.71 1.94
2000 2.21 1.35 1.29 1.66 1.70 0.00 1.45 1.39 1.89 2.06
Coverage of 95% percentile bootstrap CI
200 95.10 95.80 91.40 96.80 97.30 100.00 94.10 88.80 96.50 97.40
500 95.10 96.70 90.80 96.90 95.60 100.00 95.50 87.80 96.60 95.80
2000 94.20 96.20 89.40 96.80 95.60 100.00 96.40 87.20 97.00 95.40
Coverage of 95% adaptive bootstrap CI
200 95.12 97.82 95.88 97.24 97.20 100.00 97.02 94.86 97.02 97.40
500 95.10 97.94 95.72 97.28 95.74 100.00 97.04 94.80 96.88 95.86
2000 94.16 96.18 97.82 96.68 95.58 100.00 96.44 97.28 96.84 95.42
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Table 3: MEAN (SD) of expected benefit in the population using model-based selection
rule(PAR) or selection rules where threshold value is nonparametrically identified (NPAR,
AUG). NPAR is associated with empirically estimator and AUG is associated with aug-
mented estimator.
Cost ratio c 0.000 0.105 0.125 0.145 0.175
N=200 PAR 0.0406 (0.0035) 0.0542 (0.0067) 0.0577 (0.0072) 0.0420 (0.0080) 0.0213 (0.0075)
NPAR 0.0337 (0.011) 0.0474 (0.0136) 0.0514 (0.0136) 0.0368 (0.0127) 0.0179 (0.0106)
AUG 0.0353 (0.0097) 0.0484 (0.0128) 0.0523 (0.0126) 0.0376 (0.0117) 0.0187 (0.0092)
N=500 PAR 0.042 (0.0012) 0.0572 (0.002) 0.0611 (0.0022) 0.0459 (0.0025) 0.0257 (0.0035)
NPAR 0.0385 (0.006) 0.0536 (0.0066) 0.0577 (0.0067) 0.0426(0.0071) 0.0227 (0.007)
AUG 0.0395 (0.0044) 0.0539 (0.0061) 0.0579 (0.0065) 0.0427 (0.0071) 0.0227 (0.0069)
N=2000 PAR 0.0427 (3e-04) 0.0585 (5e-04) 0.0626 (6e-04) 0.0476 (7e-04) 0.028 (8e-04)
NPAR 0.0415 (0.002) 0.0571 (0.0022) 0.0611 (0.0024) 0.0463 (0.0024) 0.0266 (0.0032)
AUG 0.0417 (0.0016) 0.0572 (0.0022) 0.0612 (0.0023) 0.0463 (0.0024) 0.0264 (0.0035)
Table 4: Estimate and 95%CI of expected benefit in DCCT example.
Cost ratio c 0 0.05 0.10 0.12
EB(c) 0.005 (0, 0.166) 0.019 (0, 0.123) 0.035 (0.001, 0.102) 0.028 (0, 0.119)
PEB
l(c) 0.005 (0 ,0.166) 0.05 (0.031 ,0.157) 0.086 (0.029 ,0.149) 0.084 (0.029 ,0.149)
PEBu(c) 0.206 (0.157 ,0.352) 0.242 (0.192 ,0.335) 0.267 (0.216 ,0.329) 0.261 (0.211 ,0.343)
SEB
l(c) 0.023 (0 ,0.498) 0.08 (0 ,0.382) 0.131 (0.003 ,0.334) 0.107 (0.001 ,0.366)
SEB
u(c) 1 (1 ,1) 0.388 (0 ,0.802) 0.408 (0.026 ,0.809) 0.333 (0.005 ,0.823)
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Figure 1: Expected benefit curves of HBA1C and the bounds for perfect biomarker for
guiding the prevention of micro-albuminuria in the DCCT example.
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Table 1: Performance of naive and cross-validated estimates of expected benefit. PAR
indicates model-based selection rule, NPAR and AUG are selection rules where threshold
value is nonparametrically identified. NPAR is associated with empirically estimator and
AUG is associated with augmented estimator.
Cost ratio c 0.000 0.105 0.125
PAR NPAR AUG PAR NPAR AUG PAR NPAR AUG
N = 200 EB(c; βˆ)? 0.0406 0.0337 0.0353 0.0542 0.0474 0.0484 0.0577 0.0514 0.0523
Naive∗ 0.0454 0.0586 0.0568 0.0518 0.0653 0.0659 0.0485 0.0625 0.0636
CV† 0.0391 0.0403 0.0394 0.0380 0.0393 0.0384 0.0327 0.0342 0.0336
N = 500 EB(c; βˆ) 0.0420 0.0385 0.0395 0.0572 0.0536 0.0539 0.0611 0.0577 0.0579
Naive 0.0439 0.0513 0.0506 0.0559 0.0633 0.0637 0.0531 0.0608 0.0616
CV 0.0410 0.0418 0.0414 0.0501 0.0509 0.0502 0.0463 0.0471 0.0464
N = 2000 EB(c; βˆ) 0.0427 0.0415 0.0417 0.0585 0.0571 0.0572 0.0626 0.0611 0.0612
Naive 0.0433 0.0468 0.0465 0.0588 0.0622 0.0623 0.0575 0.0607 0.0609
CV 0.0428 0.0432 0.0432 0.0575 0.0579 0.0575 0.0555 0.0558 0.0555
Cost ratio c 0.145 0.175
PAR NPAR AUG PAR NPAR AUG
N = 200 EB(c; βˆ) 0.0420 0.0368 0.0376 0.0213 0.0179 0.0187
Naive 0.0429 0.0580 0.0595 0.0318 0.0488 0.0510
CV 0.0256 0.0274 0.0275 0.0129 0.0155 0.0171
N = 500 EB(c; βˆ) 0.0459 0.0426 0.0427 0.0257 0.0227 0.0227
Naive 0.0462 0.0549 0.0559 0.0313 0.0417 0.0431
CV 0.0389 0.0397 0.0390 0.0234 0.0245 0.0243
N = 2000 EB(c; βˆ) 0.0476 0.0463 0.0463 0.0280 0.0266 0.0264
Naive 0.0480 0.0519 0.0523 0.0293 0.0339 0.0344
CV 0.0462 0.0465 0.0462 0.0274 0.0278 0.0274
EB(c; βˆ)? is expected benefit of a treatment selection rule based on estimated risk model given
cost ratio c;
Naive∗ is the naive estimate of EB(c; βˆ)? based on training data;
CV† is the estimate of EB(c; βˆ)? based on random cross-validation.
Table 2: Cross-Validated estimates of EB(c) in DCCT example.
Cost ratio c 0 0.05 0.10 0.12
PAR(Naive) 0.005 0.019 0.035 0.028
PAR(CV) 0.0051 0.016 0.020 0.012
NPAR(CV) 0.0060 0.018 0.022 0.012
AUG(CV) 0.0072 0.021 0.023 0.013
2
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Supplementary Appendix
Here we provide rough sketches of the proofs of theorems stated in the paper.
Appendix A. Proof of Theorems 1 and 2
We assume the following conditions hold:
i)
√
N (βˆ − β) = n−1/2∑ni=1 I(β)l(β)i+ op(1)
ii) ρ0 − ρ1 6= c
iii) E(Risk0(β)− Risk1(β)) is differentiable with respect to β at the true β value
iv) EB(c; β), E(Risk0(β)− Risk1(β))+, E(Risk0(β)), E(Risk0(β) +Risk1(β)− 1) are dif-
ferentiable with respect to β at the true β value
We prove the result for EB(c) and the proofs for PEBl(c) and PEBu(c) in Theorem 2
follow similar arguments.
√
N
{
ÊB(c)−EB(c)
}
=
√
N
{
1
N
N∑
i=1
(
∆ˆi − c
)
+
− E (∆− c)+
}
−
√
N
{(
1
N
N∑
i=1
∆ˆi − c
)
+
− I(ρ0 − ρ1 > c)
}
=
√
N
{
1
N
N∑
i=1
(
∆ˆi − c
)
+
− 1
N
N∑
i=1
(∆i − c)+
}
+
√
N
{
1
N
N∑
i=1
(∆i − c)+ − E(∆− c)+
}
−
√
N
{(
1
N
N∑
i=1
∆ˆi − c
)
+
− (ρ0 − ρ1 − c)+
}
=
√
N
[
E
{
∆(βˆ) > c
}
+
− E(∆− c)+
]
+
√
N
{
1
N
N∑
i=1
(∆i − c)+ − E(∆− c)+
}
− A+ op(1)
where A =
√
N
{(
1
N
N∑
i=1
∆ˆi − c
)
+
− (ρ0 − ρ1 − c)+
}
=
√
N
{(
1
N
N∑
i=1
∆ˆi − c
)
+
−
(
1
N
N∑
i=1
∆i − c
)
× I(ρ0 − ρ1 − c > 0)
}
+
√
N
{(
1
N
N∑
i=1
∆ˆi − c
)
× (Iρ0 − ρ1 − c > 0) − (ρ0 − ρ1 − c)+
}
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which when ρ0 − ρ1 6= c by equi-continuity equals to
√
N × (ρ0 − ρ1 − c)×
{
I
(
1
N
N∑
i=1
∆ˆi − c > 0
)
− I(ρ0 − ρ1 − c > 0)
}
+
√
N
{
1
N
N∑
i=1
∆ˆi − (ρ0 − ρ1)
}
× I(ρ0 − ρ1 − c > 0) + op(1)
=
√
N
{
1
N
N∑
i=1
∆ˆi − (ρ0 − ρ1)
}
× I(ρ0 − ρ1 − c > 0) + op(1),
which equals to
√
N
{∑N
i=1 ∆ˆi/N − (ρ0 − rho1)
}
for ρ0−ρ1 > c and equals to 0 for ρ0−ρ1 <
c.
Appendix B. Proof of Theorem 3 and Corollary 1
We prove the result for EB(c) as the proofs for PEBl(c) and PEBu(c) are similar.
Suppose τN is a positive sequence of random variables converging to zero almost surely
with n and satisfying
√
NτN → ∞ almost surely as n → ∞. Define the event E , {|ρˆ0 −
ρˆ1− c| ≤ τN} then 1E → 1ρ0−ρ1=c in probability. Thus, the validity of the confidence interval
follows if: (i) the projection interval provides the correct coverage when ρ0− ρ1 = c; and (ii)
the standard bootstrap confidence interval provides the correct coverage when ρ0 − ρ1 6= c.
We next sketch the argument that the projection interval is valid in both (i) and (ii).
Define EBr(c) , E [∆(Y )− c]+−E(∆(Y )−c)1r≥0. We show that
√
N (ÊBr(c)−EBr(c))
and
√
N (ÊB
b
r(c)− ÊBr(c)) converge to the same limiting distribution in probability. Thus,
the validity of the proposed confidence intervals follows from standard arguments for the
validity of projection intervals (see, for example, Berger and Boos (1994)). To simplify our
proofs we assume that Y is bounded with probability one. Let l(β∗) denote the influence
function of
√
N(β̂ − β∗). Without loss of generality we assume c = 0.
For θ ∈ R2dim(Y )+2 define
∆(Y ; θ) , g−1
(
θ0 + θ
T
2 Y
)− g−1 (θ0 + θ1 + (θ2 + θ3)TY ) ,
4
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where g is the logit function. Note that ∆(Y ) = ∆(Y ; β) and ∆̂(Y ) = ∆(Y ; β̂). Define
∆˙(Y ; θ) , (d/dθ)∆(Y ; θ), then for any compact set K ⊆ R2dim(Y )+2 the class of functions
{||∆˙(y; θ)|| : Rdim(Y ) → R , θ ∈ K} is Donsker (see, for example, Kosorok (2008)). Write ÊN
to denote expectation with respect to the empirical distribution. Then
√
N(ÊBr(0)−EBr(0)) =
√
N
(
ÊN
[
∆̂(Y )
]
+
− ÊN∆̂(Y )1r≥0
)
−
√
N
(
E [∆(Y )]+ − E∆(Y )1r≥0
)
,
which we can expand to equal
√
NÊN
([
∆̂(Y )
]
+
− [∆(Y )]+
)
− ÊN
√
N
(
∆̂(Y )−∆(Y )
)
1r≥0
+
√
N (ÊN − E)
(
[∆(Y )]+ −∆(Y )1r≥0
)
,
which equals
ÊN
([
ZN (Y ) +
√
N∆(Y )
]
+
−
[√
N∆(Y )
]
+
)
+
√
N(ÊN − E)
(
[∆(Y )]+ −∆(Y )1r≥0 − 1r≥0E(∆˙(Y ; β∗)T )l(β∗)
)
+ oP (1),
where ZN ,
√
N(∆̂(Y ) − ∆(Y )) = ∆˙(Y ; β˜)T√N(β̂ − β∗) for some β˜ intermediate to β̂
and β∗. We now argue that the leading term in the above display is equal to
√
N(ÊN −
E)∆˙(Y ; β∗)T l(β∗)1∆(Y )≥0 + oP (1). The leading term in the above display is equal to
ÊNZN (Y )1∆(Y )≥01√N |∆(Y )|≥|ZN (Y )|
+ ÊN
([
ZN (Y ) +
√
N∆(Y )
]
+
−
[√
N∆(Y )
]
+
)
1√N |∆(Y )|≤|ZN (Y )|. (1)
Note that P
(
|√N∆(Y )| ≤ |ZN (Y )|
)
is bounded above by
P
(
|∆(Y )| ≤ sup
y∈supp(Y )
||∆˙(y; β˜)|| ||β̂ − β∗||
)
≤ 2C sup
y∈supp(Y )
||∆˙(y; β˜)|| ||β̂ − β∗|| = oP (1),
where C is an upper bound on the density of ∆(Y ). Using |[a + b]+ − [b]+| ≤ [a]+ the sec-
ond term in (1) is bounded above in magnitude by ÊN [ZN (Y )]+ 1
√
N |∆(Y )|≤|ZN | = oP (1).
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The first term in (1) is equal to ÊNZN (Y )1∆(Y )≥0 + oP (1), which in turn is equal to
E∆˙(Y ; β∗)T1∆(Y )≥0
√
N(ÊN −E)l(β∗) + oP (1).
Assembling the arguments made above, it follows that
√
N(ÊBr(0)− EBr(0)) = νT
√
N(ÊN − E)
 [∆(Y )]+∆(Y )1r≥0
l(β∗)
 + oP (1),
where ν = (1, 1r≥0, E∆˙(Y ; β∗)T (1∆(Y )≥0 − 1r≥0))T .
Following the same arguments, it can be shown that
√
N(ÊB
b
r(0)− ÊBr(0)) equals
√
N(ÊB
b
r(0) − EBbr(0)) = νT
√
N(ÊN −E)
 [∆(Y )]+∆(Y )1r≥0
l(β∗)
 + oP b(1),
where ν is defined as above and we write rN = oP b(1) to mean P
b(|rN | ≥ ) = oP (1) for any
 > 0. Note that
√
N (∆̂b(Y ) − ∆̂(Y )) = ∆˙(Y ; β˜)T√N(ÊbN − ÊN)I(β∗) + oP b(1) where β˜ is
intermediate to β̂b and β̂, and
P
(
|∆̂(Y )| ≤ sup
y∈supp(Y )
||∆˙(y; β˜)|| ||β̂b − β̂||
)
≤ P
(
|∆(Y )| ≤ sup
y∈supp(Y )
||∆˙(y; β˜)|| ||β̂b − β̂||+ sup
y∈supp(Y )
|∆̂(y)−∆(y)|
)
= oP b(1),
where again β˜ is intermediate to β̂b and β̂.
It remains to show that the bootstrap confidence interval for ÊB(c) is consistent when
ρ0−ρ1 6= 0. In the above notation this requires showing
√
N(ÊB
b
ρˆb
0
−ρˆb
1
(0)− ÊB ρˆ0−ρˆ1(0)) and
√
N(ÊBρˆ0−ρˆ1(0) − EBρ0−ρ1(0)) converge to the same limiting distributions in probability.
However, since ρˆ0− ρˆ1 is a regular, (strongly) consistent estimator of ρ0−ρ1 and ρ0−ρ1 6= 0,
it follows that
√
N(ÊB
b
ρˆb
0
−ρˆb
1
(0)− ÊBρˆ0−ρˆ1(0)) =
√
N(ÊB
b
ρ0−ρ1(0) − ÊBρ0−ρ1(0)) + oP b(1),
and
√
N(ÊBρˆ0−ρˆ1(0)− EBρ0−ρ1(0)) =
√
N(ÊBρ0−ρ1(0)− ÊBρ0−ρ1(0)) + oP (1).
Thus, the projection interval proof for r = ρ0 − ρ1 applies.
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Appendix C. Details supporting Remark 2
Remark 2: [Locally consistent confidence interval for EB(c).]
For any η ∈ Rdim(β) and r ∈ R define
θ̂(η, r) , ÊN∆(Y ; β̂N)1∆(Y ;η)≥0(1− c)− ÊN (∆(Y ; η)− c)1r−c≥0,
θ(η, r) , E∆(Y ; β)1∆(Y ;η)≥0(1− c) −E(∆(Y ; η)− c)1r−c≥0.
Note that θ(β,E∆(Y ; β)) = EB(c). For every fixed η, r pair it can be shown that
√
N (θ̂(η, r)−
θ(η, r)) is regular, asymptotically normal, and for any δ ∈ (0, 1) a (1− δ)× 100% confidence
interval for θ(β,E∆(Y ; β)) can be obtained via the bootstrap. Denote such an interval by
ξδ(η, r). Thus, were β
∗ and E∆(Y ; β) known, one could bootstrap
√
N
(
θ̂(β,E∆(Y ; β))− θ(β,E∆(Y ; β))
)
(but holding β and E∆(Y ; β) to be fixed) to obtain
a valid confidence interval for θ(β,E∆(Y ; β)). Of course, neither β nor E∆(Y ; β) are known;
however, for any α ∈ (0, 1) standard methods can be used to construct a (1 − α) × 100%
joint confidence region for (β,E∆(Y ; β)), say Γα. Then, it follows that⋃
(η,r)∈Γα
ξδ(η, r),
is a valid (1−δ−α)×100% confidence interval for θ(β,E∆(Y ; β)) = EB(c). This procedure
involves the union of smooth, regular, confidence intervals and is therefore also regular (i.e.,
locally consistent). The above interval takes a union over a larger set and is therefore
potentially more conservative than the interval described in Section 4.2. On the other hand,
a smooth density for ∆(Y ) is no longer required (details omitted).
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